Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Updates from CAPTIVATE: ibrutinib and venetoclax for CLL

Tanya Siddiqi • 17 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Ibrutinib Venetoclax
CAPTIVATE

Tanya Siddiqi, MD, of the City of Hope National Medical Center, Duarte, CA, discusses the efficacy and safety results of the use of ibrutinib and venetoclax for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Tanya Siddiqi

0:59
The potential of combination therapies to improve CAR-T outcomes in patients with CLL
Tanya Siddiqi • 10 Dec 2023
0:54
A research update in Richter's transformation from ASH 2023
Tanya Siddiqi • 10 Dec 2023
3:12
Liso-cel in R/R CLL: 24-month follow-up of TRANSCEND-CLL-004
Tanya Siddiqi • 10 Dec 2023
Novel therapies in NHL: BTK inhibitors & degraders
Nirav Niranjan Shah et al. • 17 Oct 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals